Related Experiment Video
Updated: Jul 6, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of
Salman Punekar1, Samantha Zak, Valerie G Kalter
1Wilkes University, Wilkes-Barre, PA 18766, USA.
Summary
Thrombospondin 1 (TSP-1) protects against inflammatory bowel disease (IBD). TSP-1 deficiency worsens colitis, while antiangiogenesis therapy with ABT-510 improves outcomes, suggesting TSP-1
Area of Science:
- Gastroenterology
- Immunology
- Vascular Biology
Background:
- Inflammatory bowel disease (IBD) is associated with vascular abnormalities and proangiogenic factors.
- Thrombospondin 1 (TSP-1) possesses known antiangiogenic and anti-inflammatory properties.
Purpose of the Study:
- To investigate the role of TSP-1 in inflammatory bowel disease (IBD) using a dextran sulfate sodium (DSS) mouse model.
- To evaluate the therapeutic potential of antiangiogenesis treatment in IBD.
Main Methods:
- TSP-1-deficient (TSP-1-/-) and wild-type (WT) mice were administered DSS for 7 days.
- Disease activity, myeloperoxidase (MPO) activity, histology, and microvascular density (MVD) were assessed.
- Protein levels of key angiogenic and inflammatory factors were measured; mice were treated with the TSP peptide ABT-510.
Main Results:
- TSP-1-/- mice exhibited exacerbated colitis, characterized by severe rectal bleeding, increased crypt damage, and deeper lesions.
- Higher MPO activity and significantly increased MVD were observed in TSP-1-/- mice.
- Treatment with ABT-510 significantly reduced the clinical severity of colitis and angiogenesis.
Conclusions:
- TSP-1 acts as a protective factor in IBD.
- Antiangiogenesis therapy, exemplified by ABT-510, shows promise as an adjuvant treatment for IBD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...